

Ruben J Colman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2342726/publications.pdf>

Version: 2024-02-01

34
papers

812
citations

687363

13
h-index

713466

21
g-index

35
all docs

35
docs citations

35
times ranked

1342
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1569-1581. | 1.3 | 388 |
| 2 | Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 486-493. | 4.4 | 76 |
| 3 | Histological inflammation increases the risk of colorectal neoplasia in ulcerative colitis: a systematic review. <i>Intestinal Research</i> , 2016, 14, 202. | 2.6 | 48 |
| 4 | Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1639-1647. | 4.7 | 38 |
| 5 | Optimal Doses of Methotrexate Combined with Anti-TNF Therapy to Maintain Clinical Remission in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 312-317. | 1.3 | 35 |
| 6 | Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 849-860. | 1.9 | 34 |
| 7 | Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2135-2141. | 1.9 | 30 |
| 8 | Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 631-637. | 1.9 | 27 |
| 9 | Antibodies to infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 593-603. | 3.7 | 22 |
| 10 | Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 205-206. | 4.4 | 21 |
| 11 | Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 507-515. | 1.9 | 21 |
| 12 | Agreement Between Patient- and Physician-Completed Pediatric Ulcerative Colitis Activity Index Scores. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 52, 708-713. | 1.8 | 20 |
| 13 | Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1045-1051. | 1.9 | 14 |
| 14 | Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash. <i>ACG Case Reports Journal</i> , 2015, 2, 236-238. | 0.4 | 8 |
| 15 | Prevalence of functional GI disorders among pediatric patients with persistent asthma. <i>Journal of Digestive Diseases</i> , 2018, 19, 522-528. | 1.5 | 7 |
| 16 | Predicting Therapeutic Response in Pediatric Ulcerative Colitis—A Journey Towards Precision Medicine. <i>Frontiers in Pediatrics</i> , 2021, 9, 634739. | 1.9 | 7 |
| 17 | Tu1350 Vedolizumab in the Treatment of IBD: The University of Chicago Experience. <i>Gastroenterology</i> , 2015, 148, S-866. | 1.3 | 5 |
| 18 | Upper Gastrointestinal Endoscopy in Adolescents With Severe Obesity Before Vertical Sleeve Gastrectomy. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 69, 287-291. | 1.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Endoscopic and Histologic Response and Remission in Inflammatory Bowel Disease Patients Initiating Vedolizumab. <i>American Journal of Gastroenterology</i> , 2015, 110, S783-S784. | 0.4 | 4 |
| 20 | Sa1998 "But I'm Feeling Fine!" A Comparison of Parent and Child Symptom-Report Among Pediatric Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 148, S-379-S-380. | 1.3 | 1 |
| 21 | Fecal Alpha 1-Antitrypsin as a Biomarker for Disease Activity in Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2014, 109, S434. | 0.4 | 1 |
| 22 | Efficacy of High-Dose Versus Low-Dose Methotrexate in Combination Therapy for Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2014, 109, S489-S490. | 0.4 | 0 |
| 23 | Sa1141 Assessment of Injection Site Reactions Related to Anti-TNF Therapies in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 148, S-238. | 1.3 | 0 |
| 24 | Tu1351 Crohn's Disease Patients Currently or Previously on Natalizumab Can Be Safely and Effectively Switched to Vedolizumab. <i>Gastroenterology</i> , 2015, 148, S-866-S-867. | 1.3 | 0 |
| 25 | Tu1349 The Efficacy and Safety of Calcineurin Inhibitors in Inducing and Maintaining Clinical Remission in IBD Patients Commencing Vedolizumab. <i>Gastroenterology</i> , 2015, 148, S-866. | 1.3 | 0 |
| 26 | Su2014 Revised Predictive Values for IBD Colitis-Associated Neoplasia in the Modern Era. <i>Gastroenterology</i> , 2015, 148, S-575. | 1.3 | 0 |
| 27 | P-031 "Segmental and Total Abdominal Colectomies are Safe Management Strategies for Colitis-Associated Neoplasia. <i>Inflammatory Bowel Diseases</i> , 2016, 22, S19. | 1.9 | 0 |
| 28 | Sa1970 Antibodies to Infliximab are Frequently Present when Infliximab Levels are Detectable in an ECLIA-based Assay. <i>Gastroenterology</i> , 2016, 150, S420. | 1.3 | 0 |
| 29 | 1160 REAL-WORLD PEDIATRIC INFLIXIMAB PHARMACOKINETIC MODEL VERIFIES CRITICAL NEED FOR PRECISION DOSING SOFTWARE. <i>Gastroenterology</i> , 2020, 158, S-233-S-234. | 1.3 | 0 |
| 30 | Mo1895 POPULATION PHARMACOKINETIC BAYESIAN ESTIMATES AND VEDOLIZUMAB INDUCTION EXPOSURE PREDICT 1-YEAR STEROID-FREE CLINICAL REMISSION IN PEDIATRIC IBD. <i>Gastroenterology</i> , 2020, 158, S-967-S-968. | 1.3 | 0 |
| 31 | 613 ANTIBODIES TO INFLIXIMAB ACCELERATE DRUG CLEARANCE WHILE INTENSIFICATION STRATEGIES REVERSE IMMUNOGENICITY AND RECAPTURE CLINICAL RESPONSE. <i>Gastroenterology</i> , 2020, 158, S-130-S-131. | 1.3 | 0 |
| 32 | An 11-Month-Old With Vomiting, Altered Mental Status, and Hypoventilation. <i>Clinical Pediatric Emergency Medicine</i> , 2020, 21, 100764. | 0.4 | 0 |
| 33 | Can Baseline Histological Score Predict Subsequent Clinical Outcomes in Patients With Ulcerative Colitis?. <i>American Journal of Gastroenterology</i> , 2015, 110, S799. | 0.4 | 0 |
| 34 | 22 CHANGE IN FECAL CALPROTECTIN AND LACTOFERRIN PREDICT CLINICAL REMISSION FOLLOWING INDUCTION THERAPY WITH INFLIXIMAB IN PEDIATRIC CROHN'S DISEASE (CD). <i>Gastroenterology</i> , 2020, 158, S112. | 1.3 | 0 |